soul trial oral semaglutide cardiovascular outcomes results 2024 2025 Updates in Medicine on X: "SOUL (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in SOUL: Oral Semaglutide Bests Usual
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13



























